AIOMEGA to present pediatric and adult airway studies at SLEEP 2026

By AI, Created 6:08 AM UTC, May 18, 2026, /AGP/ – AIOMEGA will present three peer-reviewed studies at SLEEP 2026 in Baltimore on June 15-16, highlighting airway changes in children and adults using its AIO Breathe platform. The company says the data could help reduce repeated titrations and support a more predictable approach to oral appliance therapy for mild and moderate obstructive sleep apnea.

Why it matters: - AIOMEGA is trying to position oral appliance therapy as a more predictable option for mild and moderate obstructive sleep apnea and snoring in both children and adults. - The company says its approach could reduce recurring titrations, treatment fatigue, time and cost for patients and clinicians. - The SLEEP 2026 presentations could strengthen the case for growth-responsive pediatric airway management and multilevel airway optimization across ages 6-17 and adults.

What happened: - AIOMEGA announced that it will present three peer-reviewed scientific studies at the AASM/APSS SLEEP 2026 Annual Meeting in Baltimore on June 15-16. - The company will exhibit at Booth #968. - The presentations focus on structural, functional and physiologic airway improvements across pediatric and adult populations. - AIOMEGA develops the AIO Breathe family of FDA-cleared pediatric and adult oral appliances for mild and moderate OSA and snoring.

The details: - One study evaluates adult and pediatric OSA outcomes using AAVOAT, short for Adaptive Antero-Vertical Optimization of Airway Therapy. - The AAVOAT study covers mild and moderate OSA, plus severe OSA as exploratory research. - AIOMEGA says the data show multilevel airway improvements in both adults and children. - A second presentation covers growth-responsive pediatric airway development in ages 6-17. - That pediatric work uses dentist-guided, multidisciplinary OSA management with growth-responsive protocols and AAVOAT-modeled airway targets. - The pediatric presentation reports structural, functional and physiologic improvements using noninvasive imaging and clinical follow-up. - A third study examines TAVMLR and TAVMLRD airway optimization with CBCT visualization. - That work reports observed changes including incremental airway expansion and hyoid elevation using TAVMLRD geometry. - The CBCT study includes multi-segmented adult and pediatric airway management and comparative volumetric visualization of airway changes at the start of therapy. - AIOMEGA is also highlighting SMART Rx and AIO Rx as tools to help clinicians evaluate patient-specific considerations before a device is built. - SMART Rx is not intended to replace clinician judgment. - The platform combines these tools with AIO Breathe’s patented antero-vertical mandibular-lingual repositioning. - AIOMEGA says that combination is designed to minimize recurring titrations and reduce the burden associated with traditional OSA therapy. - The pediatric platform supports the company’s FDA-cleared ages 6-17 program for mild-moderate OSA and snoring. - AIOMEGA says the pediatric pathway aligns airway support with craniofacial development, dentition changes and multidisciplinary care. - AIOMEGA partners with the Sleep Medicine Institute of Texas to integrate the nine-step BROSAR program, short for Body Recomposition and OSA Reduction. - BROSAR emphasizes body recomposition, metabolic health and lifestyle transformation rather than weight loss alone. - The program also supports nutrition, hydration, exercise and behavioral modification. - The AIOMEGA App is a therapy-agnostic monitoring platform available on Android and Apple devices. - The app aggregates data from treatment pathways including CPAP, oral appliances from any manufacturer, post-surgical patients, positional therapy and athletic training. - The app can also be used without devices to promote a healthier way of life. - The app displays information from third-party wearable devices, including oxygenation, respiratory rate, heart rate and HRV, sleep architecture representations, blood pressure and continuous glucose monitoring data. - The app also tracks hydration and nutrition metrics, food labels and recipes, activity, steps, run and walk tracking, calorie burn calculations, weight-management goals and exercise targets. - AIOMEGA is based in Tyler, Texas. - The company says it has FDA clearance for its pediatric devices under 510(k) K252525 and for its adult devices under 510(k) K233754. - More information is available in the company’s announcement.

Between the lines: - AIOMEGA is framing its platform as a lifetime airway strategy, from childhood growth through adult care. - The emphasis on imaging, modeled airway targets and pre-build clinical decision support suggests the company is trying to differentiate on customization rather than repeated device adjustments. - The broader app and lifestyle components show AIOMEGA linking oral appliance therapy with monitoring and behavior-change tools.

What’s next: - AIOMEGA will present the three studies at SLEEP 2026 in Baltimore on June 15-16. - Clinicians, researchers and industry partners can visit Booth #968 to review SMART Rx, AIO Rx, AIO Breathe devices, growth-responsive pediatric pathways and the AIOMEGA App. - The company’s next test will be whether the observational data and visualization claims translate into broader clinical adoption.